New search    Hide text from Guidelines

This group comprises preparations used in the treatment of Parkinsons disease and related conditions, including drug-induced parkinsonism.

Bromocriptine used in parkinsonism is classified in this group (e.g. tablets of 5 mg and 10 mg). Low strength bromocriptine tablets (e.g. 2.5 mg) used as a prolactine inhibitor are classified in G02CB - Prolactine inhibitors.
Cabergoline used in parkinsonism is classified in this group (e.g. tablets of 1 mg). Low strength cabergoline tablets (0.5 mg) used as a prolactine inhibitor are classified in G02CB.
Lisuride in high strength formulations (e.g. 0.2 mg tablets), which is also used in the treatment of Parkinsonism, are classified in G02CB while lisuride in low strength formulations (e.g. 25 mcg tablets) are classified in N02CA.

ATC code	Name	DDD	U	Adm.R	Note
N04BC01	bromocriptine	40	mg	O
N04BC02	pergolide	3	mg	O
N04BC03	dihydroergocryptine mesylate
N04BC04	ropinirole	6	mg	O
N04BC05	pramipexole	2.5	mg	O	hydrochloride
N04BC06	cabergoline	3	mg	O
N04BC07	apomorphine	20	mg	P
N04BC08	piribedil	0.2	g	O
N04BC09	rotigotine	6	mg	TD	patch

List of abbreviations